Prognostic Value of Fusobacterium nucleatum after Abdominoperineal Resection for Anal Squamous Cell Carcinoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic Value of Fusobacterium nucleatum after Abdominoperineal Resection for Anal Squamous Cell Carcinoma
Authors
Keywords
-
Journal
Cancers
Volume 14, Issue 7, Pages 1606
Publisher
MDPI AG
Online
2022-03-23
DOI
10.3390/cancers14071606
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Microbiome and pancreatic ductal adenocarcinoma
- (2021) Annemilaï Tijeras-Raballand et al. Clinics and Research in Hepatology and Gastroenterology
- Prognostic value of intratumoral Fusobacterium nucleatum and association with immune-related gene expression in oral squamous cell carcinoma patients
- (2021) Cindy Neuzillet et al. Scientific Reports
- Multicentre Investigation of Prognostic Factors Incorporating p16 and Tumour Infiltrating Lymphocytes for Anal Cancer After Chemoradiotherapy
- (2021) K. Wakeham et al. CLINICAL ONCOLOGY
- The human tumor microbiome is composed of tumor type–specific intracellular bacteria
- (2020) Deborah Nejman et al. SCIENCE
- Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer
- (2020) G. Serna et al. ANNALS OF ONCOLOGY
- Treatment algorithm and prognostic factors for patients with stage I–III carcinoma of the anal canal: a 20-year multicenter study
- (2020) Diane Bruyere et al. MODERN PATHOLOGY
- Fusobacterium nucleatum is associated with worse prognosis in Lauren’s diffuse type gastric cancer patients
- (2020) Ellen Teresa Boehm et al. Scientific Reports
- The Intersection between Oral Microbiota, Host Gene Methylation and Patient Outcomes in Head and Neck Squamous Cell Carcinoma
- (2020) Zigui Chen et al. Cancers
- Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1
- (2019) Chamutal Gur et al. OncoImmunology
- Intratumoral Fusobacterium nucleatum levels predict therapeutic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma
- (2019) Kensuke Yamamura et al. CLINICAL CANCER RESEARCH
- Fusobacterium nucleatum Contributes to the Carcinogenesis of Colorectal Cancer by Inducing Inflammation and Suppressing Host Immunity
- (2019) Jiao Wu et al. Translational Oncology
- The gut microbiota influences anticancer immunosurveillance and general health
- (2018) Bertrand Routy et al. Nature Reviews Clinical Oncology
- Fusobacterium nucleatum and colorectal cancer: A review
- (2018) Fu-Mei Shang et al. World Journal of Gastrointestinal Oncology
- Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection
- (2016) Wulfran Cacheux et al. BRITISH JOURNAL OF CANCER
- Biomarkers in anal cancer: from biological understanding to stratified treatment
- (2016) Christopher M Jones et al. BRITISH JOURNAL OF CANCER
- Association ofFusobacterium nucleatumwith immunity and molecular alterations in colorectal cancer
- (2016) Katsuhiko Nosho WORLD JOURNAL OF GASTROENTEROLOGY
- Fusobacterium nucleatumin colorectal carcinoma tissue and patient prognosis
- (2015) Kosuke Mima et al. GUT
- Binding of the Fap2 Protein of Fusobacterium nucleatum to Human Inhibitory Receptor TIGIT Protects Tumors from Immune Cell Attack
- (2015) Chamutal Gur et al. IMMUNITY
- Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis
- (2015) Kei Mitsuhashi et al. Oncotarget
- Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) R. Glynne-Jones et al. ANNALS OF ONCOLOGY
- Anal carcinoma – Survival and recurrence in a large cohort of patients treated according to Nordic guidelines
- (2014) Otilia Leon et al. RADIOTHERAPY AND ONCOLOGY
- Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: Formal consensus method for the development of guidelines for standardised time-to-event endpoints’ definitions in cancer clinical trials
- (2012) Carine A. Bellera et al. EUROPEAN JOURNAL OF CANCER
- Signature patterns of human papillomavirus type 16 in invasive anal carcinoma
- (2012) Séverine Valmary-Degano et al. HUMAN PATHOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started